Volumetric Perfusion CT for Early Assessment of Response to Anti-angiogenic Therapy in Metastatic Renal Cell Carcinoma
Alexander Sterzik, MD; Melvin D’Anastasi, MD; M. Staehler, MD; Maximilian Reiser, MD; Anno Graser, MD
Departments of Clinical Radiology and Urology, University Hospital Grosshadern, Munich, Germany | 09-03-2015
A 46-year-old male patient, with a right-sided partial nephrectomy due to papillary renal cell carcinoma one year ago, presented with tumor recurrence and new metastases in the right paracolic gutter and right abdominal wall. He was scheduled for anti-angiogenic tyrosin-kinase-inhibitor (TKI) therapy. Serial volumetric perfusion-CT scans of a selected representative metastatic lesion were performed, before as well as seven days after commencement of the anti-angiogenic TKI therapy, for noninvasive monitoring of early treatment response.
The outcomes by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.